<!DOCTYPE HTML>
	<html lang="en">
	<head>
		<title>Journal reading</title>
		<meta charset="utf-8">
		<meta name="viewport" content="width=792, user-scalable=no">
		<meta http-equiv="x-ua-compatible" content="ie=edge">
		<link rel="stylesheet" href="shower/themes/ribbon/styles/screen.css">
    		<style type="text/css" media="all">
	        section.slide p.source {
            		color: #000;
            		position: absolute;
            		bottom: 10px;
            		right: 10px;
            		text-align: right;
            		font-size: 0.8em;
            		margin: 0px;
        	}   
        	section.slide p.source a {
            		color: #000;
        	}
        	table.clean td img {
            		vertical-align: top;
        	}
        	table.clean td {
            		background: none;
        	}
    		</style>
	</head>
	<body class="list">
		<header class="caption">
			<h1>Journal reading</h1>
			<p>2014-01-13<br />
			Ra-223 treatment for metastatic prostate cancer</p>
		</header>
		<section class="slide cover" id="Cover"><div>
			<h2>Ra-223 treatment for metastatic prostate cancer</h2> 
			<p>Kaohsiung Veterans General Hospital <br />
			Department of Nuclear Medicine <br />
			<a href="http://www.mcdlee.tw">Sin-di Lee</a></p>
			<img src="pictures/cover.jpg" alt="">
			<!--
				To apply styles to the certain slides
				set slide ID to get needed elements
				-->
			<style>
				#Cover h2 {
					margin:30px 0 0;
					color:#FFF;
					text-align:center;
					font-size:60px;
					}
				#Cover p {
					margin:10px 0 0;
					text-align:center;
					color:#FFF;
					font-style:italic;
					font-size:20px;
					}
				#Cover p a {
					color:#FFF;
					}
			</style>
		</div></section>

		<section class="slide"><div>
			<h2><a href="http://www.jnccn.org/content/11/12/1471.abstract" target="_blank">NCCN, Version 1.2014</a></h2>
			<p align="center"><a href="pictures/nccn.jpg"><img src="pictures/nccn.jpg" width="560 px"/></a></p>
	</div></section>
	<section class="slide" id="Reference"><div>
	<h2>Reference</h2>
	<ol>
		<li><i>Sartor O, Hoskin P, Bruland OS.</i> Targeted radio-nuclide therapy of skeletal metastases. <a href="http://www.ncbi.nlm.nih.gov/pubmed/22534284" target="_blank">Cancer Treat Rev. 2013;39(1):18-26.</a></li>
		<li><i>Pinto A, Cruz P.</i> Radium-223 chloride: a new treatment option for metastatic castration-resistant prostate carcinoma. <a href="http://www.ncbi.nlm.nih.gov/pubmed/23190319" target="_blank">Drugs R D. 2012;12(4):227–233.</a> </li>
		<li><i>Parker C, Nilsson S, Heinrich D, et al.</i> Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer. <a href="http://www.ncbi.nlm.nih.gov/pubmed/23863050" target="_blank">New England Journal of Medicine. 2013;369(3):213–223.</a></li>
	</ol>	
	</div></section>
	<section class="slide" id="intro"><div>
	<h2>Bony metastases in prostate cancer</h2>
	<p>More than 90% of patients with metastatic castration-resistant prostate cancer (mCRPC) have radiologic evidence of bone metastases.</p>
	<style>
		#intro li {
		font-size:22px;
		}
	</style>
	<ul class="next">
		<li>major cause of death and disbility</li>
		<li>decreased quality of life</li>
		<li>Increased treatment cost</li></ul>
	<p class="next">Unlike other cancers, deaths from prostate cancer are often due to <mark>bone disease</mark> and its complication.</p>
	</div></section>
	<section class="slide"><div>
	<h2>Mechanism of bony metastasis</h2>	
	<blockquote>
		<p>Seed and soil</p>
	</blockquote>
	<figcaption>Stephen Paget, Lancet 1889</figcaption>
	<p><strong>Both</strong> tumor cells and a variety of stromal cells interact with a number of <em>secreted <mark class="important">paracrine factors </mark></em> in a “vicious cycle” that promotes the survival and proliferation of tumor cells.</p>
	</div></section>
	<section class="slide"><div>
	<h2>Micro-environment</h2>
	<p>In bone, cells such as the osteoblasts, osteoclasts, and hematopoietic cells (and their precursors) also represent components of the tumor micro-environment.</p>
	<ul><li class="next"><mark class="important">Osteoclast activating factors</mark> are thought to be critical in enabling tumor growth to be established in bone, working in part through RANKL.</li>
	<li class="next">Experiments with fibroblasts derived from bone stroma combined with prostate cancer cell lines display <mark class="important">synergistic growth</mark>.</li></ul>
	</div></section>
	<section class="slide"><div>
	<h2>Variable bony metastases</h2>
	<ul>
		<li>Relative lytic: myeloma and renal cell carcinoma</li>
		<li>Relative osteoblastic: prostate cancer</li>
		<li>Mixed lytic/blastic: breast cancer</li>
	</ul>
	<p>It is the tumor associated <strong>upregulated osteoblastic activity</strong> that promotes new bone formation and incorporation of the ‘bone seeking radioisotopes’ (BSRs) used therapeutically.</p>
	</div></section>
	<section class="slide"><div>
	<h2>Combination of other drugs</h2>
	<p>The uptake of BSRs is proportional to the osteoblastic nature of the bone metastatic disease.</p>
	<ul>
		<li>Bisphosphonates and RANKL antagonist (eg: denosumab) alter the lytic/blastic ratio in bone lesions after chronic administration.</li>
		<li>Bortezomib treatment in myeloma has also been shown to increase bone scan up take.</li>
	</ul>
	</div></section>
	<section class="slide"><div>
	<h2>Flare up </h2>
	<p>Another approach to increase BSR uptake is through exploiting the ‘flare’ seen after LHRH agonists or abiraterone used in prostate cancer or after hormonal therapies in breast cancer.</p>
	<p>Timing BSR therapy administration to take advantage of this flare is an unexplored but attractive concept.</p>
	</div></section>
	<section class="slide"><div>
	<h2>Mechanism of Denosumab and Biphosphates</h2>
	<p align="center"><img src="pictures/mechanism1.jpg" width="600 px" /></p>
	<p class="source">http://www.pallimed.org/2011/07/denosumab-palifermin-and-costs-of.html</p>
	</div></section>
	<section class="slide"><div>
	<img src="pictures/f1.jpg" width="450 px"/>
	<p>Bone scans in a breast-cancer patient before/after chronic bisphosphonate therapy</p>
	</div></section>
	<section class="slide"><div>
	<img src="pictures/f2.jpg" width="450 px"/>
	<p>Alteration of Tc-99 MDP bone scan uptake in myeloma after bortezomib treatment</p>
	</div></section>
	<section class="slide" id="BSR"><div>
	<h2>Selected BSRs</h2>
	<style>
		#BSR th {font-size: 15px }
		#BSR td {font-size: 15px }
	</style>
	<table>
	<tr>
		<th>Isotope</th>
		<th>Half-life</th>
		<th>Targeting agents</th>
		<th>Particle</th>
		<th>Max energy (MeV)</th>
		<th>Mean energy</th>
		<th>Penetration</th></tr>
	<tr>
		<th>Ra-223</th>
		<td>11.4 d</td>
		<td>-</td>
		<td>Alpha</td>
		<td>27.78</td>
		<td>6.94</td>
		<td><0.1 mm </td></tr>
	<tr>
		<th>Sr-89</th>
		<td>50.5 d</td>
		<td>-</td>
		<td>Beta</td>
		<td>1.46</td>
		<td>0.58</td>
		<td>2.4 mm</td></tr>
	<tr>
		<th>Sm-153</th>
		<td>1.9 d</td>
		<td>EDTMP</td>
		<td>Beta</td>
		<td>0.81</td>
		<td>0.22</td>
		<td>0.5 mm</td></tr>
	<tr>
		<th>P-32</th>
		<td>14.3 d</td>
		<td>-</td>
		<td>Beta</td>
		<td>1.71</td>
		<td>0.69</td>
		<td>3.0 mm</td></tr>
	<tr>
		<th>Y-90</th>
		<td>2.7 d</td>
		<td>Citrate</td>
		<td>Beta</td>
		<td>2.27</td>
		<td>0.93</td>
		<td>4.0 mm</td></tr>
	<tr>
		<th>Lu-177</th>
		<td>6.7 d</td>
		<td>EDTMP</td>
		<td>Beta</td>
		<td>0.49</td>
		<td>0.14</td>
		<td>0.3 mm</td></tr>
	<tr>
		<th>I-131</th>
		<td>8.0 d</td>
		<td>HDBP</td>
		<td>Beta</td>
		<td>0.61</td>
		<td>0.19</td>
		<td>0.8 mm</td></tr>
	<tr>
		<th>Re-186</th>
		<td>3.8 d</td>
		<td>HEDP/etidronate</td>
		<td>Beta</td>
		<td>1.07</td>
		<td>0.33</td>
		<td>1.0</td></tr>
	<tr>
		<th>Re-188</th>
		<td>0.7 d</td>
		<td>HEDP</td>
		<td>Beta</td>
		<td>2.12</td>
		<td>0.64</td>
		<td>3.8</td></tr>
	<tr>
		<th>Ho-166</th>
		<td>1.1 d</td>
		<td>DOTMP/EDTMP</td>
		<td>Beta</td>
		<td>1.84</td>
		<td>0.67</td>
		<td>3.3 mm</td></tr>
	<tr>
		<th>Sn-117m</th>
		<td>13.6 d</td>
		<td>DTPA</td>
		<td>Conversion electron</td>
		<td>0.15</td>
		<td>0.14</td>
		<td>0.2</td></tr>
	</table></div></section>
	<section class="slide"><div>
	<h2>Decay chain of Ra-223</h2>
	<div style="float:left"><img src="pictures/decay_chain.png" width="220 px"/></div>
	<p class="source">http://en.wikipedia.org/wiki/Decay_chain</p>
	<div style="float:right"><ul>
		<li>4n+3 Decay chain, 4 alpha and 2 beta</li>
		<li>Less penetrant in tissue.</li>
		<li>Cellular repair after alpha particle <br /> induced damage is much less efficient.</li></ul></div>
	</div></section>
	<section class="slide cover" id="sep1"><div>
			<style>
			#sep1 h2 {
				margin:120px 0 0;
				color:#FFF;
				text-align:center;
				font-size:120px;
				}
			</style>
	<h2>Clinical trial</h2>
	<img src="pictures/cover.jpg" alt="">
	</div></section>
	<section class="slide"><div>
	<h2>Phase I trial of Ra-223</h2>
	<p>Published in 2005, 25 p'ts with bone mets from breast or prostate cancer received <strong>single injection</strong> of Ra-223 with different dose: <br />
	46, 93, 163, 213 or 250 kBq/kg and follow 8 weeks.</p>
	<ul><li class="next">No dose-limiting hematotoxicity.</li>
	<li class="next">Reversible myelosupression in some p'ts with nadirs at 2-4 wks.</li>
	<li class="next">10 diarrhea, 9 bone pain, 5 nausea, 5 vomiting. </li></ul>
	</div></section>
	<section class="slide"><div>
	<h2>Phase II trial of Ra-223</h2>
	<p>Published in 2007, only enrolled CRPC p'ts (2004-02 ~ 2005-05). Randomized to received:</p>
	<ul>
	<li class="next">EBRT + placebo</li>
	<li class="next">EBRT + Ra-223 (Four repeated monthly injections, 50 kBq/kg/dose)</li></ul>
	</div></section>
	<section class="slide"><div>
	<h2>Phase II trial of Ra-223 - cont.</h2> 
	<img src="pictures/phaseII.png"/>
	</div></section>
	<section class="slide" id="phaseII_result"><div>
	<style>
		#phaseII_result th {font-size: 15px }
		#phaseII_result td {font-size: 15px }
	</style>
	<h2>Phase II trial of Ra-223 - cont.</h2>
	<table>
	<tr>
		<th>Outcome</th>
		<th>Ra-223</th>
		<th>Placebo</th>
		<th>P value</th></tr>
	<tr>
		<td>Median relative change in bone ALP level</td>
		<td>-65.6%</td>
		<td>9.3%</td>
		<td><0.0001</td></tr>
	<tr>
		<td>Other tumor markers <br /> (total ALP, PINP, CTX-1, ICTP)</td>
		<td></td>
		<td></td>
		<td>significant</td></tr>
	<tr>
		<td>Median time to SREs</td>
		<td>14 wks</td>
		<td>11 wks</td>
		<td>0.065<br />Hazard ratio: 1.75</td></tr>
	<tr>
		<td>Median relative change PSA level <br />(baseline and 4 wks after last injection)</td>
		<td>-23.8%</td>
		<td>44.9%</td>
		<td>0.003</td></tr>
	<tr>
		<td>Median time to PSA progression</td>
		<td>26 wks</td>
		<td>8 wks</td>
		<td>0.048</td></tr>
	<tr>
		<td>Median overall survival</td>
		<td>65.3 wks</td>
		<td>46.4 wks</td>
		<td>0.066 <br />Harzard ratio: 2.12</td></tr>
	<tr>
		<td>Myelotoxicity and other side effect</td>
		<td></td>
		<td></td>
		<td>not different</td></tr>
	</table>
	</div></section>
	<section class="slide"><div>
	<h2>Second phase II trial</h2>
	<p>Published in 2012. Randomized, double-blind.</p>
	<p>Aimed to investigate the <mark>dose-response relationship and pain-relieving effect</mark> in CRPC with bone metastases.</p>
	<p class="next">100 p'ts were randomized to received different doses of a single injection (5, 25, 50 or 100 kBq/kg).</p>
	</div></section>
	<section class="slide"><div>
	<h2>Second phase II trial - cont.</h2>
	<table>
		<tr>
		<th>Dose</th>
		<th>5</th>
		<th>25</th>
		<th>50</th>
		<th>100</th></tr>
		<tr>
		<td>W2</td>
		<td colspan="4"> Significant difference, p = 0.035</tr>
		<tr>
		<td>W8, pain responders</td>
		<td>40%</td>
		<td>63%</td>
		<td>56%</td>
		<td>71%</td></tr>
		<tr>
		<td>Complete response in responders</td>
		<td>30%</td>
		<td>42%</td>
		<td>44%</td>
		<td>52%</td></tr>
		<tr>
		<td>Overall survival</td>
		<td colspan="4">50 wk. No diff.</td></tr></table>
	</div></section>
	<section class="slide"><div>
	<h2>Second phase II trial - Side effect</h2>
	<p>About 97% of patients reported at least one side effect.</p>
	<p>Hematologic events were generally not severe, with slightly greater rates in the two highest-dose groups. Most frequent: anemia (11%) and Hb decrease (15%).</p>
	<p>Most freq. non-hematologic AEs: nausea, vomiting, diarrhea, constipation, peripheral edema and bone pain. No difference across dose groups.</p>
	</div></section>
	<section class="slide"><div>
	<h2>Second phase II trial - cont.</h2>
	<p>These two trials suggested efficacy of Ra-223 in p'ts with mCRPC, in both symptomatic improvement and prolongation of survival, and with a favorable safety profile.</p>
	</div></section>
	<section class="slide"><div>
	<h2>Phase III trial - ALSYMPCA trial</h2>
	<p>Alpharadin in Symptomatic Prostate Cancer Patients study.</p>
	<p>Double-blind, RCT, placebo-controlled study.</p>
	<p>Primary end point: OS <br />
	Secondary end points: time to the first SRE, time to total ALP progression and normalization, total ALP response, time to PSA progression, safety and QoL.</p>
	</div></section>
	<section class="slide" id="Phase3Pts"><div>
	<style> #Phase3Pts li {font-size: 10 px;}</style>
	<h2>Phase III trial - Patients</h2>
	<p>A total of 921 p'ts were randomized on a 2:1 basis to receive Ra-223 (2008-06~2011-02).</p>
	<ul>
		<li class="next">CRPC, with two or more bony metastases and no visceral metastasis.</li>
		<li class="next">P'ts had received docetaxel, but not healthy enough or declined to receive it, or it was not available.</li>
		<li class="next">PSA >= 5 ng/mL, with evidence of progression</li>
		<li class="next"> ECOG <=2, Life expectary >= 6 months</li>
		<li class="next">Adequate hematologic, renal and liver function</li></ul>
	</div></section>
	<section class="slide"><div>
	<h2>Phase III trial - Exclusion criteria</h2>
	<ul>
		<li class="next">C/T within 4 wks or had not recovered from AE due to C/T.</li>
		<li class="next">previous hemibody external R/T</li>
		<li class="next">systemic radiotherapy with radioisotopes within the previous 24 wks</li>
		<li class="next">a blood transfusion or use of EPO within the previous 4 wks</li>
		<li class="next">LN involvement that was more than 3 cm in the short-axis diameter</li>
		<li class="next">visceral metastases</li>
		<li class="next">imminent or established spinal cord compression</li></ul>
	</div></section>
	<section class="slide"><div>
	<h2>Phase III trial - Protocol</h2>
	<p>50 kBq/kg/dose, 6 injection every 4 wks.</p>
	<p>P'ts with CRPC during maintenance treatments were required to continue the treatment throughout the study.</p>
	<p>Analgesic medication or EBRT for symptom control.</p>
	</div></section>
	<section class="slide"><div>
	<h2>Phase III trial - Flowchart</h2>
	<img src="pictures/III_flow_chart.jpg" width="100%"/>
	</div></section>
	<section class="slide"><div>
	<h2>Phase III trial - Result </h2>
	<p>The interim results were analyzed after 314 events and in light of these results the Independent Data monitoring Committee (IDMC) <mark>recommened stopping the trial early</mark>, because there was evidence of a significant OS benifit favoring Ra-223.</p>
	</div></section>
	<section class="slide"><div>
	<p align="center"><img src="pictures/table1.jpg" width="500 px"/></p>
	</div></section>
	<section class="slide"><div>
	<p align="center"><img src="pictures/table1-1.jpg" width="500 px" /></p>
	<p>Baseline clinical characteristics was balanced between the study group.</p>
	</div></section>
	<section class="slide"><div>
	<h2>Phase III trial - Result 2</h2>
	<p>The safety population included 901 pt's (600 in Ra-223 group).</p>
	<p>The planned interim analysis was based on data from 809 p'ts (541 in Ra-223 group).</p>
	<table>
		<tr>
		<th>Group</th>
		<th>Completed 6 injection</th>
		<th>Median number of injection</th></tr>
		<tr>
		<td>Ra-223</td>
		<td>387, 63%</td>
		<td>6</td></tr>
		<tr>
		<td>Placebo</td>
		<td>145, 47%</td>
		<td>5</td></tr>
	</table>
	</div></section>
	<section class="slide"><div>
	<h2>Phase III trial - Efficacy</h2>
	<p align="center"><img src="pictures/III_OS_curve.jpg" /></p>
	</div></section>
	<section class="slide"><div>
	<h2>Phase III trial - Efficacy cont.</h2>
	<p align="center"><img src="pictures/III_time_Skeletal.jpg" /></p>
	</div></section>
	<section class="slide"><div>
	<p align="center"><img src="pictures/III_subgroup.jpg" width="100%"/></p>
	</div></section>
	<section class="slide"><div>
	<p align="center"><img src="pictures/III_secondary.jpg" width="100%" /></p>
	<p>也有<a href="ref/nejmoa1213755_appendix.pdf">KM</a>可以看</p>
	</div></section>
	<section class="slide" id="III_safety"><div>
	<style>
		#III_safety th {font-size: 15px }
		#III_safety td {font-size: 15px }
	</style>
	<h2>Phase III study - Safety</h2>
	<p>Adverse events rate was onsistently lower in the Ra-223 group than in the placebo group.</p>
	<table>
		<tr>
		<th>Group</th>
		<th>All AEs</th>
		<th>Grade 3 or 4 AEs</th>
		<th>Seriour AEs</th>
		<th>Withdraw study-drug</th></tr>
		<tr>
		<td>Ra-223 n=600</td>
		<td>558, 93%</td>
		<td>339, 56%</td>
		<td>281, 47%</td>
		<td>99, 16%</td></tr>
		<tr>
		<td>Placebo n=301</td>
		<td>290, 96%</td>
		<td>188, 62%</td>
		<td>181, 60%</td>
		<td>62, 21%</td></tr>
	</table>
	</div></section>
	<section class="slide" id="III_safety2"><div>
	<style>
		#III_safety2 th {font-size: 15px }
		#III_safety2 td {font-size: 15px }
	</style>
	<h2>Phase III study - Safety - cont.</h2>
	<ul>
	<li><a href="pictures/III_AEs.jpg">Table 3</a> shows AEs occurred more at least 5% of p'ts.</li>
	<li>Overall, no clinically meaningful differences in the frequency of grade 3 or 4 adverse events were noted.</li></ul>
	<table>
	<tr>
		<th>Group</th>
		<th>Ra-223</th>
		<th>Placebo</th></tr>
	<tr>
		<th>Disease progression</th>
		<td>11%</td>
		<td>12%</td></tr>
	<tr>
		<th>Bone pain</th>
		<td>10%</td>
		<td>16%</td></tr>
	<tr>
		<th>Anemia</th>
		<td>8%</td>
		<td>9%</td></tr>
	<tr>
		<th>Spinal cord compression</th>
		<td>4%</td>
		<td>5%</td></tr></table>
	</div></section>
	<section class="slide"><div>
	<h2>Phase III trial - Quality of Life</h2>
	<p>More rate of patient in Ra-223 group had improvement of quality of life according to <a href="http://www.facit.org/FACITOrg/Questionnaires">FACT-P score</a>.</p>
	<p>Increasing >=10 points on a scale of 0 to 156: 25% vs 16%, P=0.02</p>
	<p>Mean change in FACT-P score from baseline to 16th wk: -2.7 vs -6.8, P=0.006</p>
	</div></section>
	<section class="slide"><div>
	<h2>Phase III trial - Discussion</h2>
	<ul>
		<li>Improving OS</li>
		<li>Prolonged time to first symptomatic SRE</li>
		<li>Improving tumor markers</li>
		<li class="next">Lower incidence of AEs</li>
		<li class="next">No increasing grade 3 or 4 hematologic AEs rate.</li></ul>
	</div></section>
	<section class="slide"><div>
	<h2>Phase III trial - Discussion - conts.</h2>
	<ul>
		<li>Liberal definition of <b>best standard of care</b> --> finding of the study may be generalizable to routine practice.</li>
		<li>Liberal definition of CRPC --> high external validity.</li>
		<li>Not suitable or not use Docetaxel is balanced between group and is compatible with routine practice.</li>
	</ul>
	</div></section>
	<section class="slide"><div>
	<h2>Phase III trial - Limitation</h2>
	<ul>
		<li>Exclusing patient with visceral metastases (25% of CRPC).</li></ul>
	</div></section>
	<section class="slide shout up"><div>
	<h2>The treatment of prostate cancer has evolved</h2>
	</div></section>
	<section class="slide"><div>
	<h2>Further studies</h2>
	<p>New data on use of cabazitaxel, abiraterone and enzalutamide is published as well.</p>
	<p>A phase 1-2 trial of Ra-223 combined with docetaxel in patients with CRPC and bone metastases is currently ongoing.</p>
	</div></section>
	<section class="slide shout"><div>
	<h2>Thank You</h2>
	</div></section>
	<!--
		To hide progress bar from entire presentation
		just remove “progress” element.
		-->
	<div class="progress"><div></div></div>
	<script src="shower/shower.min.js"></script>
	<!-- Copyright © 2013 Yours Truly, Famous Inc. -->
</body>
</html>
